Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07001280 · ClinicalTrials.gov registry record
A Study Investigating the Effectiveness and Safety of Garadacimab for Treating Patients With Hereditary Angioedema (HAE)
A clinical trial of Hereditary Angioedemas, sponsored by CSL Behring.
- Recruiting
- Registry status
- 200
- Enrollment target
- 9
- Study locations
NCT07001280 is a study of Hereditary Angioedemas that is actively recruiting participants, run by CSL Behring. The registered enrollment target is 200 participants. The trial reports 9 study locations across 9 states.
The verdict
NCT07001280, a study of Hereditary Angioedemas, is actively recruiting participants, sponsored by CSL Behring.
- RECRUITING
- Registry status
- 200 participants
- Enrollment target
- 9
- Study locations
Study Summary
This is a multinational, multicenter, prospective, observational cohort study of patients with HAE in the real-world setting. The study will include patients newly initiating garadacimab in routine clinical practice. Each participant will be followed for 48 months after index date (date of the first administration of garadacimab). Patient data will be collected from the HAE eDiary, patient medical records (MRs) and/or during a routine clinical visit and will be entered into the electronic case report form (eCRF) via an electronic data capture (EDC) system. Data pertaining to HAE attacks, prior HAE treatments, retrospective focused safety data collection, and healthcare resource utilization (HCRU) over a look-back period of 12 months prior to the enrollment will be extracted from the MR, and patients will also record retrospective HAE attack related data over a look-back period of 3 months prior to enrollment in the HAE eDiary. The primary aim of this study is to investigate the real-world effectiveness of garadacimab as measured by HAE attack rate before and after garadacimab initiation in patients with HAE over 24 months of follow-up. The study will aim to complement the data available from the clinical development program on the efficacy, safety, and health-related quality-of-life (HRQoL) in patients with HAE taking garadacimab.
Conditions Studied
Interventions
- OTHER No intervention
Study Locations (9)
Arizona
- Medical Research of Arizona - Phoenix
Maryland
- John Hopkins University - Baltimore
Missouri
- Washington University - St Louis
New Jersey
- Riverside Medical Group, Belleville - Belleville
Hesse
- HZRM Haemophilie-Zentrum Rhein Main - Frankfurt am Main
Lower Saxony
- Medizinische Hochschule Hannover - Hanover
Saxony
- Universitaetsklinikum Carl Gustav Carus TU Dresden - Leipzig
Schleswig-Holstein
- Universitaetsklinikum Schleswig Holstein - Campus Luebeck - Hamburg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2025-07-21 |
| Est. Completion | 2030-08-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07001280
The ClinicalTrials.gov registry entry for NCT07001280 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CSL Behring, which has 71 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hereditary Angioedemas appearing as the primary indexed condition, and to 1 intervention - of which No intervention is the first listed.
NCT07001280 reports 9 study locations spanning 9 distinct geographic areas - top geographies include Arizona, Maryland, Missouri.
Frequently Asked Questions
What is clinical trial NCT07001280 about?
NCT07001280 is a clinical study titled "A Study Investigating the Effectiveness and Safety of Garadacimab for Treating Patients With Hereditary Angioedema (HAE)". This is a multinational, multicenter, prospective, observational cohort study of patients with HAE in the real-world setting. The study will include patients newly initiating garadacimab in routine clinical practice. Each participant will be followed for 48 months after index date (date of the first...
What is the current status of trial NCT07001280?
This trial is currently recruiting. The enrollment target is 200 participants. The study started on 2025-07-21. Estimated completion is 2030-08-31.
What conditions does trial NCT07001280 study?
This clinical trial studies the following conditions: Hereditary Angioedemas.
What interventions are being tested in trial NCT07001280?
The interventions under investigation include: No intervention (OTHER).
Who is sponsoring clinical trial NCT07001280?
This trial is sponsored by CSL Behring, which has 71 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07001280 being conducted?
This trial has 9 study locations across Arizona, Maryland, Missouri, New Jersey, Hesse. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.